Clinical trials: Effectivity
Cerebrospinal Fluid Leakage
Study to Evaluate the Effectivity and Safety of BIOSCAFF®H Compared to DuraGen®, in Patients Undergoing Dural Repair
Study in which the presence or absence of symptoms or any health condition is observed and recorded 30 days after a cranial surgery in which the physician places a material or graft, either BIOSCAFF®H or DuraGen®, into the skull…
- Trial name
- NCT06419855
- Testing
- Human collagen matrix graft, Bovine collagen matrix graft
- Where
- 4 sites in Mexico
- Volunteers
- 2 people
- Sponsor
- Top Health S.A.P.I DE C.V.
Type2 Diabetes Mellitus
The Effectivity and Safety Study of rExenatide-4 in Chinese Type 2 Diabetes Mellitus
This research is a randomized, double-blind,controlled trial. 456 Chinese subjects with Type 2 Diabetes Mellitus will be enrolled in the trial.
- Trial name
- NCT03239119
- Testing
- rE-4 5 mcg, rE-4 10 mcg
- Volunteers
- 456 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Wet Age-related Macular Degeneration (wAMD)
Long-term Follow-up Study of AL-001 Ophthalmic Injection in Subjects with WAMD
This study is designed to evaluate long-term safety and efficacy of AL-001 ophthalmic injection following suprachoroidal space(SCS) administration in subjects with wAMD.
- Trial name
- NCT06718816
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Beijing Anlong Biopharmaceutical Co., Ltd.
Polyneuropathy
Asian Study on Cilostazol Effectivity in Neuropathies of Diabetes Mellitus Type 2-A Pilot Study in the Philippines
To describe if there are differences in the subjective, objective and electrophysiologic parameters of diabetic polyneuropathies at baseline, four (4) weeks, eight (8) weeks, and twelve (12) weeks after Cilostazol therapy.
- Trial name
- ASCEND (NCT01076478)
- Testing
- Cilostazol
- Where
- Philippines
- Volunteers
- 47 people
- Sponsor
- Otsuka Pharmaceutical, Inc., Philippines
Prostate Cancer
A Study Into the Effectivity and Safety of Firmagon, Prescribed for Treatment of Patients With Advanced Prostate Cancer
Patients eligible for hormone ablation therapy who are prescribed Firmagon will be followed for a maximum of 3 years to estimate the progression free survival.
- Trial name
- FAST-NL (NCT01215526)
- Where
- 47 sites in Netherlands
- Volunteers
- 274 people
- Sponsor
- Ferring Pharmaceuticals